Cardiorenal protection with dapagliflozin in patients with type 2 diabetes mellitus and chronic coronary syndrome undergoing percutaneous coronary intervention: a registry cross-sectional study

Cardiorenal protection with dapagliflozin in patients with type 2 diabetes mellitus and chronic coronary syndrome undergoing percutaneous coronary intervention: a registry cross-sectional study

Abstract Importance Although sodium‒glucose cotransporter-2 (SGLT2) inhibitors have cardiorenal benefits, their efficacy in patients with type 2 diabetes mellitus (T2DM) and chronic coronary syndrome (CCS) undergoing percutaneous coronary intervention (PCI) remains underexplored. Objective To evalua...

Full description

Saved in:
Bibliographic Details
Main Authors: Zinan Zhao, Naixin Zheng, Tianqi Zhang, Chi Zhang, Yuwei Li, Ming Lan, Ni Zhang, Hui Li, Hu Ai, Deping Liu
Format: Article
Language:English
Published: BMC 2025-04-01
Series:Cardiovascular Diabetology
Subjects:
Dapagliflozin
SGLT2 inhibitors
Cardiorenal protection
Type 2 diabetes mellitus
Chronic coronary syndrome
Percutaneous coronary intervention
Online Access:https://doi.org/10.1186/s12933-025-02678-9
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s12933-025-02678-9

Similar Items